

# Maturation of Overall Survival in TIVO-3 With Long-Term Follow-Up

Brian I. Rini,<sup>1</sup> Sumanta K. Pal,<sup>2</sup> Bernard Escudier,<sup>3</sup> Michael B. Atkins,<sup>4</sup> David F. McDermott,<sup>5</sup> Elena Verzoni,<sup>6</sup> Camillo Porta,<sup>7,8</sup> Vijay Kasturi,<sup>9</sup> Thomas E. Hutson<sup>10</sup>

<sup>1</sup>Vanderbilt-Ingram Cancer Center, Nashville, TN, USA; <sup>2</sup>Department of Medical Oncology and Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA; <sup>3</sup>Gustave Roussy, Villejuif, France;

<sup>4</sup>Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA; <sup>5</sup>Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center, Boston, MA, USA;

<sup>6</sup>Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; <sup>7</sup>Chair of Oncology, Department of Biomedical Sciences and Human Oncology, University of Bari Aldo Moro, Bari, Italy;

<sup>8</sup>Division of Medical Oncology, A.O.U. Consorziale Policlinico di Bari, Bari, Italy; <sup>9</sup>AVEO Oncology, Boston, MA, USA; <sup>10</sup>Texas A&M College of Medicine, Bryan, TX, USA


## Background

- Tivozanib (TIVO) is an oral vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI) that is approved by the US Food and Drug Administration for treatment of patients with relapsed/refractory (R/R) renal cell carcinoma (RCC) following  $\geq 2$  prior systemic therapies<sup>1,2</sup>
- In the TIVO-3 study (NCT02627963), treatment with TIVO demonstrated a significantly improved independent review committee-assessed progression-free survival (PFS) compared with those treated with sorafenib (SOR), with a stratified HR of 0.73 (95% CI, 0.56-0.95)<sup>3</sup>
- Similarly, long-term follow-up analyses revealed that the investigator-assessed PFS rate at 3 years was higher in patients treated with TIVO compared with those treated with SOR (12% vs 2%, respectively)<sup>4</sup>
- Maturity of survival data is a key analytic when evaluating the clinical application of oncology therapies<sup>5</sup>
- Here, we report the impact of event accumulation and data maturation on the stability of Kaplan-Meier (KM) survival estimates at serial time points of extended mean follow-up

## Methods

### Study Design

- TIVO-3 is a phase 3, global, open-label, parallel-arm study comparing TIVO with SOR in patients with R/R metastatic RCC (**Figure 1**)




BID, twice daily; CPI, checkpoint inhibitor; ECOG PS, Eastern Cooperative Oncology Group performance status; fav, favorable; IMDC, International Metastatic RCC Database Consortium; int, intermediate; mRCC, metastatic renal cell carcinoma; PO, oral; QD, once daily.

### Endpoints and Statistical Analyses

- To evaluate for effects of maturation of OS, Cox proportional hazards and log-rank statistics were used to estimate HR (95% CI) for OS using prespecified (2 years after last-patient-in [LPI], August 2019; 251 events, May 2020) and exploratory intent-to-treat (ITT) analyses (extended follow-up: 270 events, January 2021; database closure, May 2021)
- At the final data cutoff (database closure), conditional analyses of Cox proportional hazards and stratified log-rank statistics, using data from patients achieving 12-month and 18-month PFS in either arm, were used to estimate the HR and 95% CI for OS
- Patients were followed up for survival until death, consent withdrawal, or loss to follow-up

## Results

- At baseline, 350 patients were randomized to receive TIVO (n=175) or SOR (n=175)
- At 2 years following LPI, the mean follow-up was 17.9 months (data cutoff, August 2019), and 65% of patients had experienced an event, with an OS HR of 0.99 (95% CI, 0.76-1.29; **Figure 2**)
- With subsequent prespecified and exploratory OS analyses, and with mean follow-up extended to 22.8 months, 80% of patients had experienced an event, and the HR of OS lowered to 0.89 (95% CI, 0.70-1.14) in favor of TIVO (**Figure 2**)



- When OS was conditioned on clinically relevant landmark PFS time points, a statistically significant improvement in OS was observed in patients treated with TIVO compared with those treated with SOR
  - Table 1** shows the unconditioned OS in the ITT population results and the landmark PFS-conditioned OS results analyzed at final database closure (data cutoff, May 2021)
  - The HR for conditioned OS significantly favored TIVO over SOR in patients with PFS  $\geq 12$  months (HR, 0.445) and trended in favor of TIVO over SOR in patients with PFS  $\geq 18$  months (HR, 0.461)
  - Median OS was 48.3 (TIVO) vs 32.8 (SOR) months when conditioned on PFS  $\geq 12$  months, and was 54.3 (TIVO) vs 50.0 (SOR) months when conditioned on PFS  $\geq 18$  months


**Table 1. Unconditioned (ITT Population) and Landmark PFS-Conditioned OS in TIVO-3**

Population	Group	At risk, n	Events	Median OS (95% CI), months	HR (95% CI)	Stratified log-rank P value
Unconditioned (ITT population)	TIVO	175	138	16.4 (13.4-21.9)	0.89 (0.70-1.14)	0.3533
	SOR	175	142	19.1 (14.9-24.2)		
Conditioned on PFS $\geq 12$ months	TIVO	45	25	48.3 (32.8-NR)	<b>0.45 (0.22-0.91)</b>	<b>0.0221</b>
	SOR	23	17	32.8 (27.6-50.0)		
Conditioned on PFS $\geq 18$ months	TIVO	34	8	54.3 (44.9-NR)	0.46 (0.15-1.39)	0.1617
	SOR	11	5	50.0 (32.4-NR)		

NR, not reached.

- The KM survival curves for TIVO and SOR cohorts conditioned on 12-month PFS demonstrate rapid separation shortly after 1 year that appears to remain consistent or increase over time (**Figure 3**)

**Figure 3. KM Survival Curve of Conditional OS in Patients With 12-Month PFS**



## Conclusions

- Serial OS analyses using KM estimates are affected by increased curve reliability with decreased censoring and limited residual patients at risk for death
- Consistent with this concept, as events accumulated over the follow-up period, the HR for OS reduced from 0.99 to 0.89, favoring TIVO over SOR
- Conditional analysis from TIVO-3 suggests an improved OS with TIVO over SOR in the subset of patients remaining progression-free at 1 year

**Long-term follow-up in TIVO-3 suggests that early and consistent PFS benefit with TIVO over SOR may be associated with an improvement in OS HR over time as more events accumulate**


### References

- Fotivda (tivozanib). Prescribing information. Aveo Pharmaceuticals Inc; 2021.
- US Food and Drug Administration. Accessed April 27, 2022. <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approved-tivozanib-relapsed-or-refractory-advanced-renal-cell-carcinoma>.
- Rini BI, et al. *Lancet Oncol*. 2020;21:95-104.
- Atkins MB, et al. *J Clin Oncol*. 2022;40:362.
- Monnickendam G, et al. *Value Health*. 2018;21:S363.

### Acknowledgments

This study was sponsored by AVEO Oncology. Editorial assistance was provided by Clara Huesing, PhD, of SciMentum, Inc, a Nucleus Holding Ltd company, and funded by AVEO Oncology.

Copies of this poster obtained through QR (Quick Response) code are for personal use only and may not be reproduced without written permission of the authors



<https://investor.aveooncology.com>